Neuren Pharmaceuticals Ltd
ASX:NEU
Neuren Pharmaceuticals Ltd
Total Equity
Neuren Pharmaceuticals Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Total Equity
AU$363.9m
|
CAGR 3-Years
110%
|
CAGR 5-Years
92%
|
CAGR 10-Years
34%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Total Equity
AU$454.2m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Total Equity
AU$92.5m
|
CAGR 3-Years
86%
|
CAGR 5-Years
23%
|
CAGR 10-Years
51%
|
|
|
Probiotec Ltd
ASX:PBP
|
Total Equity
AU$88.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Argenica Therapeutics Ltd
ASX:AGN
|
Total Equity
AU$14m
|
CAGR 3-Years
27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Total Equity
AU$52.4m
|
CAGR 3-Years
19%
|
CAGR 5-Years
18%
|
CAGR 10-Years
9%
|
|
Neuren Pharmaceuticals Ltd
Glance View
Founded in 1993, Neuren Pharmaceuticals Ltd has carved a niche for itself within the biotech industry, focusing primarily on neurological and neurodevelopmental disorders. The company operates at the intriguing intersection of innovation and medicine, where the stakes are high, but so are the potential rewards. Neuren has its headquarters in Australia and has oriented its research towards developing therapies that could change the lives of those affected by conditions like Rett syndrome and Fragile X syndrome. By adopting a strategic approach that combines cutting-edge science with a relentless focus on unmet needs, Neuren positions itself uniquely through its proprietary compounds such as trofinetide and NNZ-2591, which are at the core of its research endeavors. The company's business model hinges on a dual approach: developing its own drugs while simultaneously fostering partnerships with larger pharmaceutical companies to bring these therapies to market. This model allows Neuren to share the substantial costs and risks inherent in drug development while benefiting from the expanse of its partners' distribution networks and market insights. Revenue generation kicks in primarily through milestone payments, royalties, and licensing agreements as these partners help navigate the rigorous phases of clinical trials and regulatory approvals. Financial stability is thus intricately tied to clinical successes and strategic alliances, allowing Neuren to balance the speculative nature of biotech investments with the promise of transformative medical breakthroughs.
See Also
What is Neuren Pharmaceuticals Ltd's Total Equity?
Total Equity
363.9m
AUD
Based on the financial report for Dec 31, 2024, Neuren Pharmaceuticals Ltd's Total Equity amounts to 363.9m AUD.
What is Neuren Pharmaceuticals Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
34%
Over the last year, the Total Equity growth was 77%. The average annual Total Equity growth rates for Neuren Pharmaceuticals Ltd have been 110% over the past three years , 92% over the past five years , and 34% over the past ten years .
You don't have any saved screeners yet